The nation of Zimbabwe has declined a substantial American health deal valued at 367 million US dollars (£272m) over five years because of Washington's demand for sensitive data.
This rejection became public after a internal memorandum from December was leaked, which showed Head of State Emmerson Mnangagwa believed the deal was "lopsided".
A government representative later clarified that the US was requesting health data for research and commercial purposes while was unwilling to share the resulting advantages from future medical innovations.
"We will now turn to the difficult and regrettable task of winding down our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for more talks to find a deal suitable to all parties so the country's vital HIV treatment initiative can continue.
Wider Background
Zimbabwe's decision comes after a similar situation in Kenya, where a high court suspended a similar deal with the US after concerns were raised about the safety of citizens' health data.
Since returning to office last year, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen aid for the US government, but Trump argued its expenditure was "inefficient" and his government was seeking direct bilateral agreements to boost transparency and accountability.
As per statements, 16 nations in Africa have to date signed similar health pacts, constituting over $18.3bn in committed funds.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership could have provided extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving HIV treatment via US-supported initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to provide its biological resources and data for a long time, with no corresponding promise of access to any medical innovations – such as new medicines or tests – that could be developed from that provided information," he stated.
"Effectively, our nation would supply the basic resources for scientific discovery with no certainty that the resulting innovations would be accessible to our population if a future health crisis arise."
National Interest and International Frameworks
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were disrupting structures already established via the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to deal with potential global health emergencies.
"This framework is intended to ensure that when a country contributes its information, the benefits – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We are open to ongoing dialogue with our American counterparts on how future collaboration might be arranged in a manner that respects the independence and interests of both nations."
Health Experts Response
Medical experts stated it recognised the government's concerns, but suggested that talks need to persist given that much of the country's Aids initiatives relied on external financing.
"In cases where technical issues arise, such as those relating to data governance or implementation frameworks, these can often be addressed via detailed discussion and mutually agreed protections," it said.
The halted deal emphasises the ongoing tensions between accepting crucial international aid and protecting a country's data in an ever more data-driven world.